342 related articles for article (PubMed ID: 15649305)
1. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
2. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment.
Ye P; Kazanjian P; Kunkel SL; Kirschner DE
J Lab Clin Med; 2004 May; 143(5):310-9. PubMed ID: 15122175
[TBL] [Abstract][Full Text] [Related]
3. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1.
Vicenzi E; Alfano M; Ghezzi S; Gatti A; Veglia F; Lazzarin A; Sozzani S; Mantovani A; Poli G
J Leukoc Biol; 2000 Sep; 68(3):405-12. PubMed ID: 10985258
[TBL] [Abstract][Full Text] [Related]
4. Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy.
Boulassel MR; Smith GH; Edwardes MD; Young M; Klein M; Gilmore N; Macleod J; Leblanc R; René P; Allan J; Lalonde RG; Routy JP
HIV Med; 2005 Jul; 6(4):268-77. PubMed ID: 16011532
[TBL] [Abstract][Full Text] [Related]
5. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of beta-chemokine levels during anti-HIV therapy.
Aleman S; Pehrson P; Sönnerborg A
Antivir Ther; 1999; 4(2):109-15. PubMed ID: 10682156
[TBL] [Abstract][Full Text] [Related]
7. Different plasma levels of interleukins and chemokines: comparison between children and adults with AIDS in China.
Jin CZ; Zhao Y; Zhang FJ; Yao HP; Wu LJ; Zhao HX; Wei HS; Wu NP
Chin Med J (Engl); 2009 Mar; 122(5):530-5. PubMed ID: 19323903
[TBL] [Abstract][Full Text] [Related]
8. A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C.
Florholmen J; Kristiansen MG; Steigen SE; Sørbye SW; Paulssen EJ; Kvamme JM; Konopski Z; Gutteberg T; Goll R
Clin Microbiol Infect; 2011 Feb; 17(2):204-9. PubMed ID: 20219081
[TBL] [Abstract][Full Text] [Related]
9. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.
Oliva A; Kinter AL; Vaccarezza M; Rubbert A; Catanzaro A; Moir S; Monaco J; Ehler L; Mizell S; Jackson R; Li Y; Romano JW; Fauci AS
J Clin Invest; 1998 Jul; 102(1):223-31. PubMed ID: 9649576
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
12. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Carter LM; Peters BS; Ellis BA; Wolstencroft RA
J Infect; 2000 Nov; 41(3):252-5. PubMed ID: 11120614
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
14. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
15. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of MIP-1beta and RANTES in HIV-1 subtype CRF01_AE infected patients with different rates of disease progression.
Chuenchitra T; Wasi C; de Souza M; Nitayaphan S; Louisirirotchanakul S; Sutthent R; Brown AE; Birx DL; Polonis VR
Southeast Asian J Trop Med Public Health; 2008 Sep; 39(5):856-62. PubMed ID: 19058580
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption.
Barqasho B; Nowak P; Tjernlund A; Kinloch S; Goh LE; Lampe F; Fisher M; Andersson J; Sönnerborg A;
HIV Med; 2009 Feb; 10(2):94-102. PubMed ID: 19200172
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
Kuntzen T; Tural C; Li B; Feldmann G; Kupfer B; Nischalke HD; Clotet B; Sauerbruch T; Rockstroh JK; Spengler U
AIDS; 2008 Jan; 22(2):203-10. PubMed ID: 18097222
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.
Forcina G; D'Ettorre G; Mastroianni CM; Carnevalini M; Scorzolini L; Ceccarelli G; D'Agostino C; Lichtner M; Massetti AP; Vullo V
Cytokine; 2004 Mar; 25(6):283-90. PubMed ID: 15036244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
